List of Excipients in Branded Drug NEBIVOLOL

Generic Drugs Containing NEBIVOLOL

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	nebivolol	0904-7189	CELLULOSE, MICROCRYSTALLINE
Major Pharmaceuticals	nebivolol	0904-7189	CROSCARMELLOSE SODIUM
Major Pharmaceuticals	nebivolol	0904-7189	FD&C BLUE NO. 2
Major Pharmaceuticals	nebivolol	0904-7189	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in NEBIVOLOL?

# Of NDCs	Excipient
33	CELLULOSE, MICROCRYSTALLINE
48	CROSCARMELLOSE SODIUM
4	CROSPOVIDONE
7	D&C RED NO. 27

Nebivolol Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Nebivolol is a mature, low-dose beta-1 adrenergic blocker with broad generic availability in the United States. The strongest excipient opportunities are not basic-copy tablets. They are low-dose content-uniformity systems, lactose-free and allergen-controlled formulations, orally disintegrating tablets, fixed-dose combinations, pediatric dosage forms, and manufacturing platforms that improve compression, dissolution, and supply-chain economics.

The core commercial constraint is price erosion. Nebivolol tablets have limited active pharmaceutical ingredient loading, which increases the relative value of excipient performance, process control, and manufacturing yield. A differentiated excipient platform must support bioequivalence, dose uniformity, stability, and efficient direct compression without creating a new regulatory burden.

What is the FDA status of nebivolol?

Nebivolol is approved in the United States as Bystolic for the treatment of hypertension. The reference product contains nebivolol hydrochloride and is supplied in 2.5 mg, 5 mg, 10 mg, and 20 mg tablets. The product is administered once daily and may be used alone or with other antihypertensive agents (U.S. Food and Drug Administration [FDA], 2007).

Attribute	Nebivolol
Reference product	Bystolic
Active ingredient	Nebivolol hydrochloride
Original U.S. sponsor	Mylan Bertek Pharmaceuticals, later commercialized through Forest Laboratories and AbbVie
U.S. approval	December 17, 2007
FDA pathway	New drug application
Main indication	Hypertension
Dosage form	Immediate-release oral tablet
Strengths	2.5 mg, 5 mg, 10 mg, 20 mg
Administration	Once daily
Current market structure	Brand and multiple generic products
Primary regulatory pathway for copies	ANDA under section 505(j)

Nebivolol is a racemic mixture of d- and l-enantiomeric components. The d-isomer has greater beta-1 receptor activity, while the l-isomer contributes to vasodilatory effects through nitric-oxide-related mechanisms. Its low dose and pharmacokinetic variability make formulation control important even though the product is an immediate-release tablet.

When did nebivolol lose exclusivity?

Nebivolol’s U.S. market exclusivity ended years ago, and generic competition is established. The original five-year new chemical entity exclusivity ran from the 2007 approval period. Any pediatric exclusivity extension would have added six months to applicable exclusivity periods, but it did not create a current barrier to generic entry.

The relevant commercial transition was from a protected branded product to an ANDA market. Generic manufacturers entered after the expiration or resolution of the principal Orange Book barriers associated with Bystolic. Generic nebivolol products are now approved and marketed in the United States.

Milestone	Timing
Bystolic FDA approval	2007
NCE exclusivity period	Approximately through 2012
Generic development and Paragraph IV activity	Primarily during the 2010s
Generic approvals and commercial entry	Primarily in the late 2010s and early 2020s
Current status	Mature generic market

What patents protect nebivolol and Bystolic?

The original nebivolol patent estate included composition, therapeutic-use, and pharmaceutical-formulation claims. The principal commercial value of that estate has expired or been overtaken by generic approvals. New commercial opportunities therefore depend more on differentiated formulations and manufacturing claims than on the original active-ingredient patent.

For a current diligence review, the relevant sources are the FDA Orange Book, Drugs@FDA, USPTO Patent Center, and federal court dockets. Orange Book entries must be assessed by product, strength, patent use code, and listed expiration date. A historical patent number without its associated use code does not establish a present barrier to an ANDA.

What was the principal nebivolol patent risk?

The main historical risks were:

• Patent claims covering nebivolol compounds or stereochemical forms.
• Pharmaceutical compositions containing nebivolol.
• Methods of treating hypertension.
• Dosage regimens and combination therapy.
• Formulation claims directed to tablet products.

The commercial relevance of these claims has declined because nebivolol is now available from multiple generic suppliers. A new excipient-based product would need claims that are technically distinct from the expired or nonblocking reference-product claims.

How strong is the current patent estate for nebivolol?

The core patent estate is weak as a barrier to conventional generic tablets. The stronger areas for new patent filings are:

1. A defined excipient ratio that produces a measurable dissolution or uniformity advantage.
2. A low-dose blend with controlled segregation and improved assay uniformity.
3. A lactose-free or sugar-free formulation with comparable stability and manufacturability.
4. An orally disintegrating dosage form with a controlled disintegration and dissolution profile.
5. A fixed-dose combination with a new active ingredient or a differentiated release profile.
6. A manufacturing process that reduces degradation, sticking, friability, or batch variability.

An excipient list alone is rarely sufficient for a robust patent. Patentability is stronger when the formulation contains a narrow quantitative range linked to unexpected performance data.

What excipients are used in nebivolol tablets?

Nebivolol tablets generally use conventional immediate-release excipients. Product-specific inactive ingredients vary by manufacturer and strength. Typical categories include:

Excipient function	Candidate materials
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate
Glidant	Colloidal silicon dioxide
Lubricant	Magnesium stearate, sodium stearyl fumarate
Wetting or dissolution aid	Polysorbate 80, poloxamer, surfactant systems
Taste modifier	Sucralose, mannitol, flavor systems for orally disintegrating products
Colorant	Approved lake dyes or iron oxides, depending on strength and market

The reference formulation should be confirmed against the current Bystolic prescribing information and DailyMed entry before a Q1/Q2 development program. Generic manufacturers commonly use different excipient systems while demonstrating pharmaceutical equivalence and bioequivalence.

What excipient strategy best fits nebivolol?

The preferred strategy depends on the target product.

Conventional generic tablet

For a standard ANDA, the development objective is low cost and reliable bioequivalence. A direct-compression or dry-granulation formulation is commercially attractive because nebivolol is administered at low doses and does not require a modified-release matrix.

A practical formulation architecture would use:

• Microcrystalline cellulose or lactose as the primary diluent.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Colloidal silicon dioxide to improve powder flow.
• Magnesium stearate or sodium stearyl fumarate for lubrication.
• A premix or geometric dilution step for nebivolol distribution.

The main technical risk is content uniformity. A 2.5 mg tablet contains a small amount of active relative to the excipient mass. Segregation during transfer, hopper discharge, or compression can produce out-of-specification assay results even when the blend passes initial sampling.

Lactose-free formulation

A lactose-free tablet could target patients with lactose intolerance, excipient restrictions, or procurement specifications that exclude animal-derived or dairy-derived materials. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, and selected starch systems are potential substitutes.

The formulation must manage:

• Higher tablet weight.
• Compactability differences.
• Hygroscopicity.
• Lubrication sensitivity.
• Disintegration performance.
• Increased raw-material cost.

A lactose-free formulation is commercially useful only if the label claim, supply-chain qualification, and patient-facing differentiation justify the incremental cost.

Orally disintegrating tablet

An orally disintegrating tablet is a more defensible product opportunity than a conventional tablet because it can address swallowing difficulty, geriatric use, and adherence. Mannitol is commonly used for mouthfeel and compactability. Crospovidone, low-substituted hydroxypropyl cellulose, or croscarmellose sodium can support rapid disintegration.

The product must control:

• Tablet friability.
• Moisture uptake.
• Packaging barrier performance.
• Mouthfeel and residual grittiness.
• Dose uniformity at the 2.5 mg strength.
• Dissolution after rapid disintegration.

A rapidly disintegrating tablet can be developed under an ANDA if it meets the applicable pharmaceutical-equivalence requirements. A substantially different dosage form or clinical use may require a 505(b)(2) strategy.

Pediatric dosage form

Nebivolol is primarily marketed for adults, but a pediatric formulation could target hypertension management where swallowing tablets is difficult. Liquid suspensions, mini-tablets, and orally disintegrating tablets are potential platforms.

The excipient profile must address pediatric acceptability, including:

• Low sugar content.
• Avoidance of unsuitable preservatives.
• Acceptable osmolality.
• Low alcohol content or alcohol-free design.
• Palatability.
• Accurate low-dose administration.
• Chemical and microbiological stability.

A pediatric product could gain value from clinical development, age-appropriate labeling, and a controlled dosing device rather than from excipient novelty alone.

What formulation patents could protect a nebivolol product?

A strong formulation patent should link composition to a measurable technical result. Potential claim categories include:

Patent theme	Potential technical result
Low-dose premix	Reduced assay variability and improved content uniformity
Co-processed excipient system	Improved flow and compression
Surfactant-assisted formulation	Faster or more consistent dissolution
Moisture-controlled tablet	Improved stability under accelerated conditions
Lactose-free matrix	Comparable hardness and disintegration without lactose
ODT platform	Disintegration within a defined time and acceptable mouthfeel
Fixed-dose combination	Reduced tablet burden and controlled release behavior
Continuous blending process	Lower blend segregation and improved batch reproducibility

The most valuable claims would include quantitative ranges for active load, particle size, excipient ratio, blend time, compression force, tablet hardness, disintegration time, and dissolution. Claims based only on the presence of familiar excipients would face substantial obviousness risk.

What generic entry risks exist for a new nebivolol product?

Generic entry risk is high for an unmodified immediate-release tablet. A new entrant would compete against approved generic products on price, supply reliability, contract-manufacturing capacity, and pharmacy substitution.

The risk profile changes by product type:

Product concept	Generic competition risk	Commercial differentiation
Standard 5 mg or 10 mg tablet	High	Low
Lactose-free tablet	Moderate	Moderate
ODT	Moderate	Moderate to high
Pediatric liquid or mini-tablet	Lower	High if clinically supported
Fixed-dose combination	Moderate	High
Novel manufacturing platform	Lower at first	Depends on patent scope and cost savings

The most credible commercial strategy is to avoid direct price competition with standard tablets. A differentiated dosage form, an institutional supply agreement, or a high-reliability manufacturing platform offers better protection.

Are there Paragraph IV challenges involving nebivolol?

Historical Paragraph IV challenges were directed at patents listed for Bystolic and related nebivolol products. The practical significance of those challenges has diminished because generic nebivolol is already approved and marketed.

For a new formulation, Paragraph IV exposure depends on whether the product references Bystolic under an ANDA or relies on a 505(b)(2) application. A formulation sponsor could face:

• Orange Book patent litigation after certification.
• A 30-month stay triggered by timely litigation.
• Label carve-out disputes for method-of-use patents.
• Patent infringement claims directed to excipient ratios or dosage forms.
• Settlement restrictions affecting launch timing.

The strongest litigation defense is a clear technical distinction from listed claims, supported by formulation records and non-infringement analysis before filing.

What is the Orange Book status of nebivolol?

Nebivolol has an established FDA reference product and generic equivalents. Orange Book analysis should distinguish:

• Bystolic listed patents.
• Any listed patents for combination products.
• Active ingredients and dosage strengths.
• Use codes tied to approved labeling.
• Patent expiration and pediatric extensions.
• Approved ANDA applicants.

The existence of an Orange Book listing does not automatically block every formulation. A listed method-of-use patent may be avoided through a section viii statement or a label carve-out if the proposed labeling does not include the patented use.

Is biosimilar risk relevant to nebivolol?

No. Nebivolol is a chemically synthesized small molecule, not a biologic. Biosimilar competition under the Public Health Service Act is not relevant. The applicable competitive threats are conventional generics, authorized generics, reformulated products, and fixed-dose combinations.

Which commercial opportunities are strongest?

Excipient suppliers

Excipient companies can pursue nebivolol through:

• Co-processed direct-compression systems.
• Low-dose blending platforms.
• Fast-disintegrating ODT bases.
• Lactose-free and allergen-controlled systems.
• Moisture-barrier packaging and formulation combinations.
• Ready-to-use premixes for contract manufacturers.

The sales proposition should focus on reduced development time, lower blend variability, fewer compression defects, and simpler scale-up.

Generic drug manufacturers

Generic companies have four realistic opportunities:

1. A low-cost, conventional ANDA tablet.
2. A differentiated lactose-free product.
3. An ODT or mini-tablet for swallowing-impaired patients.
4. A fixed-dose combination or specialty-market product.

The first option has the lowest development risk but the weakest margin potential. ODT and pediatric products have higher development costs and greater regulatory complexity, but they provide more defensible pricing.

Licensing and partnering

Potential licensing structures include:

• Excipient technology licensing to generic manufacturers.
• Regional rights for ODT or pediatric products.
• Contract development and manufacturing agreements.
• Co-development of fixed-dose combinations.
• Supply agreements tied to minimum annual volumes.

A formulation patent with manufacturing data is more licensable than a broad excipient concept. Buyers will focus on freedom to operate, bioequivalence probability, raw-material qualification, and whether the formulation reduces total cost per saleable tablet.

How does nebivolol compare with other beta blockers?

Drug	Typical formulation opportunity	Excipient differentiation
Nebivolol	Low-dose tablet, ODT, combination product	High relevance because of low drug loading
Metoprolol	Immediate- and extended-release products	Stronger modified-release patent history
Bisoprolol	Low-dose immediate-release tablet	Similar content-uniformity issues
Carvedilol	Immediate- and extended-release products	Larger dose and broader formulation complexity
Atenolol	Conventional tablet and liquid	Lower technical complexity
Propranolol	Multiple dosage forms	Broader pediatric and liquid opportunity

Nebivolol is most attractive for excipient innovation where a small active dose creates blending and uniformity challenges. It is less attractive for a basic tablet because generic substitution and price competition are mature.

Key Takeaways

• Nebivolol is a mature small-molecule generic market, not a biosimilar market.
• Bystolic’s core exclusivity has expired, and conventional tablets face high generic competition.
• The central formulation challenge is low-dose content uniformity, not controlled release.
• The best excipient opportunities are co-processed direct-compression systems, lactose-free tablets, ODTs, pediatric forms, and fixed-dose combinations.
• A patent should claim defined quantitative ranges tied to measurable performance.
• Excipient lists alone provide weak protection against obviousness challenges.
• Current Orange Book and USPTO review is required for any live filing or launch decision.
• A conventional generic offers speed and low cost; an ODT or pediatric product offers better differentiation.
• Commercial value is more likely to come from manufacturing reliability and dosage-form differentiation than from the active ingredient itself.

FAQs

Can nebivolol be formulated as an orally disintegrating tablet?

Yes. An ODT can use mannitol, crospovidone, croscarmellose sodium, microcrystalline cellulose, and a suitable lubricant. The formulation must demonstrate dose uniformity, rapid disintegration, acceptable mouthfeel, stability, and bioequivalence or the applicable regulatory bridge.

Is a lactose-free nebivolol tablet commercially attractive?

It can be attractive where procurement systems, patients, or markets avoid lactose. The opportunity is strongest when the product also improves compactability, stability, or supply-chain qualification. Lactose removal alone is unlikely to support a premium price in a heavily genericized market.

Can an excipient combination receive a nebivolol patent?

Yes, if the combination produces a novel and non-obvious formulation with a defined technical effect. A patent application should include comparative data against conventional diluent, binder, disintegrant, and lubricant systems.

Would a nebivolol liquid require a 505(b)(2) application?

The pathway depends on the proposed product and reference product. A materially different dosage form, new route, or new clinical use may require 505(b)(2) development rather than a conventional ANDA. The regulatory strategy must be assessed against the specific formulation and labeling.

What is the highest-value nebivolol excipient opportunity?

A low-dose, rapidly disintegrating, lactose-free tablet supported by robust content-uniformity data has the best balance of technical differentiation, patient utility, and commercial feasibility. A pediatric liquid or mini-tablet could have greater differentiation but would require more clinical, palatability, stability, and regulatory work.

References

1. U.S. Food and Drug Administration. (2007). Bystolic (nebivolol hydrochloride) prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. National Library of Medicine. (n.d.). DailyMed: Bystolic and nebivolol hydrochloride product labeling. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (2017). Abbreviated new drug application process and generic drug requirements. https://www.fda.gov/drugs/generic-drugs

5. United States Pharmacopeia. (2024). General chapter <905>: Uniformity of dosage units. In USP-NF. U.S. Pharmacopeial Convention.

6. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/